Equities

Cipla Ltd

Cipla Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,481.50
  • Today's Change20.50 / 1.40%
  • Shares traded149.43k
  • 1 Year change+16.39%
  • Beta0.4572
Data delayed at least 15 minutes, as of Nov 22 2024 05:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments79,71062,63146,494
Total Receivables, Net57,16250,29443,731
Total Inventory54,49853,67955,430
Prepaid expenses1,3291,1291,199
Other current assets, total1,7165,017422
Total current assets194,414172,750147,275
Property, plant & equipment, net59,33356,80055,473
Goodwill, net31,12029,83931,379
Intangibles, net16,01015,30117,029
Long term investments11,6676,3347,402
Note receivable - long term7,6338,1937,160
Other long term assets835560506
Total assets327,178294,633271,011
LIABILITIES
Accounts payable24,74024,57125,081
Accrued expenses6,0694,7762,133
Notes payable/short-term debt2,4701,7613,933
Current portion long-term debt/capital leases8704,182879
Other current liabilities, total18,30915,80817,106
Total current liabilities52,45851,09749,132
Total long term debt2,2542,0885,745
Total debt5,5948,03110,558
Deferred income tax1,8531,6332,440
Minority interest9593,0582,757
Other liabilities, total2,5902,6802,521
Total liabilities60,11460,55562,594
SHAREHOLDERS EQUITY
Common stock1,6151,6141,614
Additional paid-in capital16,72816,52816,317
Retained earnings (accumulated deficit)244,061210,967186,908
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total4,6604,9693,578
Total equity267,064234,078208,417
Total liabilities & shareholders' equity327,178294,633271,011
Total common shares outstanding807807807
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.